STOP-HF Trial
Valentina Cannone, Mark Ledwidge, Chris Watson, Paul M. McKie, John C. Burnett, Kenneth McDonald
Abstract
B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.
Topics & Concepts
Internal medicineMedicineCardiologyHeart failureNatriuretic peptideAldosteroneBlood pressureAdverse effectHeart Failure Treatment and ManagementCardiovascular Function and Risk FactorsPharmaceutical studies and practices